论文部分内容阅读
目的:研究探讨西格列汀预防糖耐量减低人群发展为2型糖尿病的临床疗效。方法:选取该院收治的确诊为糖耐量减低的患者50例作为研究对象,按照其预防控制措施的不同将其分为两组,对照组患者给予常规的饮食运动控制,观察组患者在对照组的基础上给予西格列汀治疗,治疗6个月后分别对两组患者的相关指标进行检测,并观察糖尿病的发病率。结果:观察组和对照组患者糖尿病发生率分别为4.0%和16.0%,观察组显著低于对照组,比较有统计学差异(P<0.05)。结论:西格列汀能有效预防糖耐量减低人群发展为2型糖尿病,效果显著,值得临床推广应用。
Objective: To investigate the clinical efficacy of sitagliptin in preventing glucose tolerance-reduced population from developing type 2 diabetes mellitus. Methods: Fifty patients diagnosed as having impaired glucose tolerance in our hospital were selected as the research objects, divided into two groups according to their prevention and control measures, the control group patients were given routine diet movement control, the observation group patients in the control group On the basis of the treatment of sitagliptin, 6 months after treatment, respectively, the two groups of patients to detect the relevant indicators, and observe the incidence of diabetes. Results: The incidence of diabetes in observation group and control group were 4.0% and 16.0% respectively. The observation group was significantly lower than the control group (P <0.05). Conclusion: Sitagliptin can effectively prevent people with impaired glucose tolerance from developing type 2 diabetes mellitus, which has a significant effect and is worthy of clinical application.